Treatment of Severe Iron Deficiency Anemia

Introduction to Severe Iron Deficiency Anemia

The European Crohn's and Colitis Organisation recommends intravenous iron as first-line treatment for severe iron deficiency anemia, particularly in patients with active inflammation or malabsorption 1
Severe anemia is defined as hemoglobin <10 g/dL, which warrants immediate consideration of intravenous iron therapy, according to the MMWR Recommendations and Reports 3, 1

For patients with severe iron deficiency anemia, the American Gastroenterological Association suggests that intravenous iron therapy is the preferred first-line treatment, as it provides rapid correction without the gastrointestinal side effects and slow response associated with oral iron 1, 2
The European Crohn's and Colitis Organisation specifically recommends IV iron as first-line treatment when hemoglobin is below 10 g/dL, particularly in the presence of active inflammation or malabsorption 1

Ferric carboxymaltose is the preferred IV iron formulation because it allows delivery of 750-1000 mg of iron in a single 15-minute infusion, compared to older formulations requiring multiple visits, as stated by the Clinical Gastroenterology and Hepatology 2

Hemoglobin should increase by approximately 2 g/dL after 3-4 weeks of treatment, according to the MMWR Recommendations and Reports 3, 4
If hemoglobin fails to rise by 1 g/dL after 4 weeks despite compliance, further evaluation is required, including MCV, RDW, and serum ferritin, as recommended by the MMWR Recommendations and Reports 3

The American College of Gastroenterology recommends that IV iron therapy is mandated in patients with hemoglobin <10 g/dL and active inflammatory bowel disease, as well as in post-bariatric surgery patients and those with celiac disease 1, 2, 4

For pregnant women with severe anemia, the Centers for Disease Control and Prevention recommend referral to a physician familiar with anemia in pregnancy for further evaluation if hemoglobin <9.0 g/dL 3
The European Crohn's and Colitis Organisation suggests that IV iron is first-line when hemoglobin <10 g/dL and clinically active disease is present in patients with inflammatory bowel disease 1

The Clinical Gastroenterology and Hepatology recommends monitoring for hypophosphatemia, especially with repeat courses within 3 months, as well as hypersensitivity reactions during and for 30 minutes after infusion 2

The American Gastroenterological Association advises against continuing oral iron beyond 4 weeks without documented hemoglobin response—switch to IV iron, and against using multiple daily doses of oral iron—once-daily dosing has similar efficacy with better tolerability 4

If anemia persists at 6 months despite appropriate iron therapy, the Praxis Medical Insights recommends reassessing for ongoing occult blood loss and evaluating for malabsorption, as well as considering hematology consultation for complex cases 4